Home > Insider Trading > Filing (0000899243-22-028113)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1062822	Lexicon Pharmaceuticals Inc.	LXRX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053890	Raymond Debbane	C/O Ulys, L.l.c. 750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1340098	Ulys, L.l.c.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1839806	Invus Us Partners Llc	C/O The Invus Group, Llc 750 Lexington Avenue 30Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-08-05	147,390	$2.50	5,451,204	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	331,545	Direct

Footnotes

Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock.
These securities are directly held by Invus US Partners LLC
These securities are directly held by Mr. Raymond Debbane.
Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.